Starpharma Holdings Limited
SPHRY · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $6 | $8 | $4 | $5 |
| % Growth | -29.4% | 90.9% | -15.9% | – |
| Cost of Goods Sold | $10 | $1 | $2 | $3 |
| Gross Profit | -$4 | $8 | $1 | $2 |
| % Margin | -63.7% | 92.4% | 28.1% | 36.9% |
| R&D Expenses | $12 | $16 | $19 | $19 |
| G&A Expenses | $3 | $4 | $4 | $3 |
| SG&A Expenses | $6 | $7 | $8 | $7 |
| Sales & Mktg Exp. | $3 | $4 | $4 | $4 |
| Other Operating Expenses | $0 | -$4 | -$1 | $0 |
| Operating Expenses | $18 | $18 | $26 | $26 |
| Operating Income | -$22 | -$11 | -$35 | -$35 |
| % Margin | -377.3% | -129.7% | -794.6% | -679.9% |
| Other Income/Exp. Net | $12 | $3 | $19 | $19 |
| Pre-Tax Income | -$10 | -$8 | -$16 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$8 | -$16 | -$16 |
| % Margin | -170.8% | -98.5% | -360.1% | -312.9% |
| EPS | -0.24 | -0.2 | -0.38 | -0.4 |
| % Growth | -20% | 47.4% | 5% | – |
| EPS Diluted | -0.24 | -0.2 | -0.38 | -0.4 |
| Weighted Avg Shares Out | 42 | 41 | 41 | 41 |
| Weighted Avg Shares Out Dil | 42 | 41 | 41 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | -$10 | -$10 | -$17 | -$16 |
| % Margin | -166.2% | -116.2% | -392.4% | -306% |